{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChangePercent": 0.84033936, "regularMarketPrice": 12.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.0, "sharesOutstanding": 23120100, "fiftyDayAverage": 12.2004, "fiftyDayAverageChange": -0.20040035, "fiftyDayAverageChangePercent": -0.01642572, "twoHundredDayAverage": 9.98345, "twoHundredDayAverageChange": 2.01655, "twoHundredDayAverageChangePercent": 0.2019893, "marketCap": 288489600, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "exchange": "FRA", "shortName": "RYVU THERAPEUTICS  ZY-,40", "longName": "Ryvu Therapeutics S.A.", "messageBoardId": "finmb_114118554", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1614841200000, "priceHint": 2, "regularMarketChange": 0.10000038, "regularMarketTime": 1683871611, "regularMarketDayHigh": 12.0, "regularMarketDayRange": "12.0 - 12.0", "regularMarketDayLow": 12.0, "regularMarketVolume": 10, "regularMarketPreviousClose": 11.9, "bid": 12.48, "ask": 12.74, "fullExchangeName": "Frankfurt", "financialCurrency": "PLN", "regularMarketOpen": 12.0, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 7.12, "fiftyTwoWeekLowChangePercent": 1.4590163, "fiftyTwoWeekRange": "4.88 - 13.36", "fiftyTwoWeekHighChange": -1.3599997, "fiftyTwoWeekHighChangePercent": -0.10179638, "fiftyTwoWeekLow": 4.88, "fiftyTwoWeekHigh": 13.36, "trailingAnnualDividendRate": 0.0, "symbol": "9Y4.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Leona Henryka Sternbacha 2", "city": "Krak\u00f3w", "zip": "30-394", "country": "Poland", "phone": "48 12 314 0200", "fax": "48 12 297 4701", "website": "https://www.ryvu.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Krak\u00f3w, Poland.", "fullTimeEmployees": 215, "companyOfficers": [{"maxAge": 1, "name": "Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc.", "title": "Founder, Pres of the Management Board & CEO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Krzysztof Daniel Brz\u00f3zka M.B.A., Ph.D.", "title": "Exec. VP, Chief Scientific Officer & VP of the Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kamil  Sitarz M.B.A., Ph.D.", "title": "COO & Member of the Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Vatnak  Vat-Ho M.B.A.", "title": "Chief Bus. Officer & Member of Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Hendrik  Nogai M.D.", "title": "Chief Medical Officer & Member of Management Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Tomasz  Nocun", "title": "Director of Investments & Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Paulina  Wolanin", "title": "HR Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}